Wall Street Zen Upgrades Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) to “Hold”

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday, Wall Street Zen reports.

DMRA has been the subject of several other research reports. Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Guggenheim assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday. They issued a “buy” rating and a $59.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $46.38.

Damora Therapeutics, Inc. Common Stock Trading Up 1.6%

Shares of NASDAQ:DMRA opened at $24.07 on Friday. The company has a market capitalization of $1.49 billion, a PE ratio of -7.14 and a beta of 1.52. Damora Therapeutics, Inc. Common Stock has a twelve month low of $15.00 and a twelve month high of $38.33. The firm has a 50 day simple moving average of $22.62 and a 200-day simple moving average of $25.68.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, November 4th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.12. As a group, equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction dated Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the acquisition, the chief executive officer owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP acquired a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $7,398,000. Squarepoint Ops LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $303,000. Finally, Arizona State Retirement System acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.